



## Exelixis to Present at the Credit Suisse 26th Annual Healthcare Conference on November 7th

October 26, 2017

-- Presentation to be webcast on [www.exelixis.com](http://www.exelixis.com) --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 26, 2017-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide an overview of the company at the Credit Suisse 26<sup>th</sup> Annual Healthcare Conference taking place November 6-8 in Scottsdale, AZ. The Exelixis presentation is scheduled for 5:20 PM EST / 2:20 PM PST on Tuesday, November 7, 2017.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.

### About Exelixis

Founded in 1994, [Exelixis, Inc.](http://www.exelixis.com) (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring them to patients globally. With growing revenues from the three resulting commercialized products – CABOMETYX®, COMETRIQ®, and COTELLIC® – we are reinvesting in our business to maximize the potential of our pipeline, which we intend to supplement with targeted business development activities and internal drug discovery, all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. For more information about Exelixis, please visit [www.exelixis.com](http://www.exelixis.com) or follow @ExelixisInc on Twitter.

*Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks.*

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171026006547/en/>

Source: Exelixis, Inc.

### Investors Contact:

*Exelixis, Inc.*

Susan Hubbard, 650-837-8194

EVP, Public Affairs and Investor Relations

[shubbard@exelixis.com](mailto:shubbard@exelixis.com)

or

### Media Contact:

*For Exelixis, Inc.*

Hal Mackins, 415-994-0040

[hal@torchcommunications.com](mailto:hal@torchcommunications.com)